Faricimab
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Faricimab
Faricimab: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Faricimab, so there is currently no new predicted indication. The drug’s recorded uses are listed below. They are the drug’s own recorded uses, not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 3 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| diabetes complications | licence in another country |
| macular edema | licence in another country |
| wet macular degeneration | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 13177M | Vabysmo | Solution for intravitreal injection 28.8 | Valid |
Safety Considerations
Data on faricimab’s key warnings and contraindications were not available in the data compiled for this report. No drug interaction records were found. Please refer to the TGA-approved Product Information (PI) for safety information.
The literature notes intraocular inflammation and increased intraocular pressure as areas to monitor with intravitreal anti-VEGF therapy (see guardrails below).
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.